Literature DB >> 9579606

Combined metaphase, interphase cytogenetic, and flow cytometric analysis of DNA content of pediatric acute lymphoblastic leukemia.

L Pajor1, K Szuhai, G Mehes, G Kosztolányi, P Jáksó, G Lendvai, I Szanyi, P Kajtár.   

Abstract

Eleven pediatric acute lymphoid leukemia patients were investigated for chromosomal aneuploidy by interphase cytogenetics using chromosome specific (peri)centromeric probes for all the somatic and sex chromosomes. Results were compared with metaphase cytogenetic and flow cytometric derived DNA aneuploidy data. Experiments performed on normal human cells using chromosome specific (peri)centromeric probes indicated that disomy could be recognized in a range of 89.1+/-2.7% (12.9)-96.8+/-0.2% (0.9) for the somatic chromosomes and in 98.1+/-0.4% (1.3) for the sex chromosomes. Using the cutoff level of the mean false monosomy and trisomy in the control cells +2 S.D., chromosome loss or gain for the somatic chromosomes could be revealed beyond a clonal ratio of 3.6-13.2% and 1.1-6.8%, respectively. The same value for the sex chromosomes was 3.5% and 0%, respectively. In 5 of 11 patients the leukemic cells proved to be diploid with all three methods at both gross DNA and chromosome levels. Interphase cytogenetics revealed chromosome loss or gain in all of the remaining six patients, however, the metaphase analysis indicated numerical aberration in only two patients. In one of them only the increased chromosome number could have been detected without identifying the chromosomes involved and in the other one the two methods indicated trisomy for a different chromosome. Flow cytometric data showed aneuploidy in three of the six aneuploid leukemia patients. The results suggest that interphase cytogenetics might be more accurate compared with flow cytometry and metaphase analysis to reveal aneuploidy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9579606

Source DB:  PubMed          Journal:  Cytometry        ISSN: 0196-4763


  5 in total

1.  Cytogenetic profile of primary pituitary germinoma.

Authors:  E Gömöri; D J Halbauer; T Dóczi; E Balázs; P Kajtár; L Pajor
Journal:  J Neurooncol       Date:  2000-12       Impact factor: 4.130

2.  Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell line.

Authors:  Yvonne de Jong; Annemiek M van Maldegem; Adrian Marino-Enriquez; Danielle de Jong; Johnny Suijker; Inge H Briaire-de Bruijn; Alwine B Kruisselbrink; Anne-Marie Cleton-Jansen; Karoly Szuhai; Hans Gelderblom; Jonathan A Fletcher; Judith V M G Bovée
Journal:  Lab Invest       Date:  2016-09-12       Impact factor: 5.662

3.  Correlation between BCR-ABL expression and tumor burden is restricted to the transition from minor to major cytogenetic response in interferon treated CML patients.

Authors:  László Kereskai; János A Vass; Mária Kneif; László Pajor
Journal:  Pathol Oncol Res       Date:  2003-10-07       Impact factor: 3.201

4.  A short-term in vivo model for giant cell tumor of bone.

Authors:  Maurice Balke; Anna Neumann; Károly Szuhai; Konstantin Agelopoulos; Christian August; Georg Gosheger; Pancras Cw Hogendoorn; Nick Athanasou; Horst Buerger; Martin Hagedorn
Journal:  BMC Cancer       Date:  2011-06-13       Impact factor: 4.430

5.  Histology, 12p status, and IMP3 expression separate subtypes in testicular teratomas.

Authors:  Dávid Semjén; Krisztina Bíró; Emese Kapitány; Endre Kálmán; Tamás Tornóczky; Béla Kajtár
Journal:  Virchows Arch       Date:  2020-03-06       Impact factor: 4.064

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.